Cargando…
Monitoring the responsiveness of T and antigen presenting cell compartments in breast cancer patients is useful to predict clinical tumor response to neoadjuvant chemotherapy
BACKGROUND: Vaccination of mice with tumors treated with Doxorubicin promotes a T cell immunity that relies on dendritic cell (DC) activation and is responsible for tumor control in vaccinated animals. Despite Doxorubicin in combination with Cyclophosphamide (A/C) is widely used to treat breast canc...
Autores principales: | Bernal-Estévez, David A., García, Oscar, Sánchez, Ramiro, Parra-López, Carlos A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769526/ https://www.ncbi.nlm.nih.gov/pubmed/29334915 http://dx.doi.org/10.1186/s12885-017-3982-1 |
Ejemplares similares
-
An immune surveillance model to monitor the response to neo-adjuvant chemotherapy treatment in breast cancer patients
por: Bernal-Estévez, David A, et al.
Publicado: (2015) -
Chemotherapy and radiation therapy elicits tumor specific T cell responses in a breast cancer patient
por: Bernal-Estévez, David, et al.
Publicado: (2016) -
Neoadjuvant chemotherapy modulates exhaustion of T cells in breast cancer patients
por: Rodríguez, Ivon Johanna, et al.
Publicado: (2023) -
Autologous Dendritic Cells in Combination With Chemotherapy Restore Responsiveness of T Cells in Breast Cancer Patients: A Single-Arm Phase I/II Trial
por: Bernal-Estévez, David A., et al.
Publicado: (2021) -
Monitoring early responses to neoadjuvant chemotherapy and the factors affecting neoadjuvant chemotherapy responses in primary osteosarcoma
por: Yu, Hong, et al.
Publicado: (2023)